Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_024b0bc5bdb82e72ea476a157d2fe8f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d22b649c54d79d7c1eabf23085b14a3e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55577 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-35 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 |
filingDate |
2006-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28fa8e486f0c57fcf06dfade3e6c0e83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc43379f5378470b820e6617c1b0b6b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c00d91aab34e8be8b4674266b669a610 |
publicationDate |
2009-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
NZ-562729-A |
titleOfInvention |
Novel method for preventing or treating M tuberculosis infection using Mtb72f fusion proteins |
abstract |
Disclosed is the use of a Mtb72f fusion protein comprising: (i) residues 8-729 of the sequence of SEQ ID No: 2 or a variant thereof having at least 90% identity thereto; or (ii) residues 4-725 of the sequence of SEQ ID No: 4 or a variant thereof having at least 90% identity thereto; and an adjuvant, wherein the Mtb72f fusion protein induces an immune response against M tuberculosis, in the manufacture of a pharmaceutical composition for preventing or treating tuberculosis reactivation in a mammal already infected with Mycobacterium tuberculosis. |
priorityDate |
2005-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |